Literature DB >> 7589333

Interleukin-1 beta enhances survival and interleukin-6 protects against MPP+ neurotoxicity in cultures of fetal rat dopaminergic neurons.

Y Akaneya1, M Takahashi, H Hatanaka.   

Abstract

To investigate the relationships between the central nervous system and interleukins, ventral mesencephalic cells from embryonic 17-day-old rats were cultured for 3 days in vitro (DIV) and exposed to interleukin-1 beta (IL-1 beta), interleukin-3 (IL-3), or interleukin-6 (IL-6) for the following 2 or 3 DIV with or without 2 microM 1-methyl-4-phenylpyridinium (MPP+). Thus, the survival of and the MPP+ neurotoxicity against the dopaminergic neurons immunostained with anti-tyrosine hydroxylase antibody were examined. For the survival studies, IL-1 beta has been shown to have a survival-promoting effect on dopaminergic neurons. This effect is initiated at a concentration between 0.1 and 1 ng/ml. In contrast to the effect of IL-1 beta, IL-3 and IL-6 failed to increase the survival of dopaminergic neurons. In MPP+ neurotoxicity analysis, only IL-6 among the three interleukins studied here has been shown to attenuate the MPP+ neurotoxicity against dopaminergic neurons in a dose-dependent manner; this neuro-protective action is apparent at a concentration of 10 ng/ml. In addition, these three interleukins did not promote glial proliferation. These findings suggest that the effects of IL-1 beta and IL-6 on dopaminergic neurons are not mediated by glial proliferation, that IL-1 beta acts as a neurotrophic factor on dopaminergic neurons, and that IL-6 is capable of protecting dopaminergic neurons from the neurotoxicity of MPP+.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7589333     DOI: 10.1006/exnr.1995.1082

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  23 in total

1.  IL6 protects MN9D cells and midbrain dopaminergic neurons from MPP+-induced neurodegeneration.

Authors:  Björn Spittau; Xiaolai Zhou; Ming Ming; Kerstin Krieglstein
Journal:  Neuromolecular Med       Date:  2012-07-08       Impact factor: 3.843

Review 2.  A review of the fetal brain cytokine imbalance hypothesis of schizophrenia.

Authors:  Urs Meyer; Joram Feldon; Benjamin K Yee
Journal:  Schizophr Bull       Date:  2008-04-11       Impact factor: 9.306

Review 3.  Interleukin 6 and cognitive dysfunction.

Authors:  Isabel Trapero; Omar Cauli
Journal:  Metab Brain Dis       Date:  2014-04-30       Impact factor: 3.584

4.  Single-Nucleotide Polymorphisms in Interleukin 6 (IL-6) Gene Are Associated with Suicide Behavior in an Iranian Population.

Authors:  Mohammad Mahdi Eftekharian; Rezvan Noroozi; Mir Davood Omrani; Zohreh Sharifi; Alireza Komaki; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  J Mol Neurosci       Date:  2018-09-30       Impact factor: 3.444

Review 5.  Critical Roles of Glutaredoxin in Brain Cells-Implications for Parkinson's Disease.

Authors:  Olga Gorelenkova Miller; John J Mieyal
Journal:  Antioxid Redox Signal       Date:  2018-01-05       Impact factor: 8.401

6.  Methylmercury induces acute oxidative stress, altering Nrf2 protein level in primary microglial cells.

Authors:  Mingwei Ni; Xin Li; Zhaobao Yin; Haiyan Jiang; Marta Sidoryk-Wegrzynowicz; Dejan Milatovic; Jiyang Cai; Michael Aschner
Journal:  Toxicol Sci       Date:  2010-04-26       Impact factor: 4.849

Review 7.  Physiological and pathological roles of interleukin-6 in the central nervous system.

Authors:  D L Gruol; T E Nelson
Journal:  Mol Neurobiol       Date:  1997-12       Impact factor: 5.590

8.  Late aging-associated increases in L-DOPA-induced dyskinesia are accompanied by heightened neuroinflammation in the hemi-parkinsonian rat.

Authors:  Kathryn Lanza; Amy E Perkins; Terrence Deak; Christopher Bishop
Journal:  Neurobiol Aging       Date:  2019-05-31       Impact factor: 4.673

9.  The role of interleukin-1, interleukin-6, and glia in inducing growth of neuronal terminal arbors in mice.

Authors:  Clare L Parish; David I Finkelstein; Wanida Tripanichkul; Abhay R Satoskar; John Drago; Malcolm K Horne
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

Review 10.  Therapeutic potential of nerve growth factors in Parkinson's disease.

Authors:  T J Collier; C E Sortwell
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.